Urologic oncologist Nirmish Singla, M.D., M.S.C.S., discusses our unique approach to treating patients with kidney cancer, including our latest research and clinical trials. Dr. Singla joined the Brady Urological Institute in 2020 as the Director of Translational Research in Genitourinary Oncology. He also helps lead the multidisciplinary Kidney Cancer Program at Johns Hopkins.
the kidney cancer program at Johns Hopkins offers world class, multidisciplinary clinical care, coupled with collaborative research to improve the lives of patients with kidney cancer. As leaders in the field, we strive to be at the forefront of innovation and discovery with the patient centered focus. Johns Hopkins is, ah, high volume center for kidney cancer, and we perform over 200 Effect Amis each year, including open laparoscopic and robotic approaches integrating minimally invasive and newer technologies for our surgical management. Johns Hopkins We review all high risk cases in our weekly multidisciplinary genital urinary tumor board conferences attended by leading experts in medical oncology, radiation oncology, urologic surgery, pathology and radiology to establish a group consensus for each and every patient to ensure personalized care. The kidney cancer program at Johns Hopkins is uniquely composed of a multidisciplinary clinical and translational team, combining the clinical expertise of urologic surgeons, medical oncologists, radiation oncologists, pathologists, radiologists and pathologists with the scientific and technical expertise of immunologists, epidemiologists, engineers and bio informatics shins. Mhm, yeah, we lied Several scientific research efforts and clinical trials spending the complete spectrum of kidney cancer, including both localized disease in advanced metastatic disease, Our research programs include Immuno Oncology, Biomarker Development, novel Therapeutics, Molecular imaging and Steri attacked IQ programs. And we have formed numerous collaborations across the campus of Johns Hopkins as well as with other institutions. Externally, some of our recent discoveries and ongoing research efforts have included the identification of blood based and urine based biomarkers for the earlier and more accurate detection of kidney cancer. Developing novel imaging platforms such as the system maybe pet scan to help differentiate benign from malignant kidney masses. Engineering newer surgical technologies for minimally invasive techniques to treat tumor surgically identification of prognostic and predictive biomarkers. Cataloging small renal masses to better characterize their biology and clinical behavior through perhaps the largest and most comprehensive prospective registry of small renal masses. And combining multimodal approaches to the treatment of advanced or metastatic kidney cancers, incorporating techniques such as systemic therapies, steri attacked IQ radiation and surgery. Our goal is to help scientific discoveries in the laboratory materialized for patients affected by kidney cancers. In doing so, we value a precision oncology approach that is customized to each and every patient. To learn more about the kidney cancer program or to refer a patient with kidney cancer to Johns Hopkins, please feel free to contact the Brady Urological Institute